A new clinical trial has found that taking low doses of LSD twice a week does not reduce symptoms of attention-deficit/hyperactivity disorder in adults more than a placebo. While both the LSD and placebo groups showed improvements over six weeks, there was no meaningful difference between the two. These results challenge popular claims about the benefits of microdosing psychedelics and emphasize the importance of placebo-controlled studies when evaluating treatments that are often promoted through anecdotal evidence. The research was published in JAMA Psychiatry.
Attention-deficit/hyperactivity disorder, more commonly known as ADHD, affects nearly three percent of adults worldwide. The condition involves persistent difficulties with attention, impulsivity, and hyperactivity, often leading to significant struggles in…